<DOC>
	<DOCNO>NCT00416845</DOCNO>
	<brief_summary>This study design assess effect two dos FTY720 lung ( pulmonary ) cardiac ( heart ) function healthy volunteer .</brief_summary>
	<brief_title>Effects FTY720 Heart Lung Functions Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Healthy , nonsmoking , ( ie . 6 month w/o use nicotine nicotine contain product ) , male female subject . Female subject must either surgically sterilize ( include bilateral tubal ligation ) least 6 month postmenopausal . Postmenopausal woman must regular menstrual bleeding least 1 year prior inclusion menopause confirm plasma FSH level &gt; 40 IU/L . Male subject agree refrain sperm donation checkin 30 day beyond conclusion study event . Male subject must agree use condom spermicide sexual intercourse 14 day prior checkin 30 day beyond last dose study drug . Resting heart rate â‰¥ 50 beat per minute ( bpm ) History presence clinically significant event , opinion investigator , would jeopardize safety subject impact validity study result . Subjects systolic blood pressure &lt; 90 mmHg diastolic blood pressure &lt; 50 mmHg Male subject QTcB &gt; 450 msec Female subject QTcB &gt; 470 msec Subjects pulmonary symptom , history exerciseinduced asthma , asthma chronic obstructive pulmonary disease ( COPD ) Use prescription drug within 1 month start study Positive urine screen alcohol drug screening , unless test show falsely positive confirmation test . Hemoglobin &lt; 12g/dL Donation blood significant blood loss within 56 day prior check . Donation plasma within 7 day prior check . Participation investigational study within 30 day prior check . Positive screen test HIV Hepatitis B C. A past history cigarette smoke &gt; 10 packyears use nicotine nicotinecontaining product 6 month prior dose . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>pharmacodynamic effect , cardiac effect , healthy subject , synthetic sphingosine 1 phosphate ( S1P ) receptor modulator</keyword>
	<keyword>Healthy male female subject</keyword>
</DOC>